The invention is concerned with novel diazepan derivatives of formula (I)
wherein A, X, R
3
, R
4
, R
5
, R
6
, R
8
, R
9
, R
10
, R
11
, R
12
, R
13
, m and n are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR-2 receptor, CCR-5 receptor and/or CCR-3 receptor and can be used as medicaments.
The invention is concerned with novel heterocyclyl compounds of formula (I):
wherein A, X, R3, R4, R5, R6, R7, R8, R9, R10, m, n and p are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR2 receptor, CCR5 receptor and/or CCR3 receptor and may be used as medicaments.
The invention is concerned with novel diazepan derivatives of formula (I)
wherein A, X, R3, R4, R5, R6, R8, R9, R10, R11, R12, R13, m and n are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR-2 receptor, CCR-5 receptor and/or CCR-3 receptor and can be used as medicaments.